177 related articles for article (PubMed ID: 37540513)
21. Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis.
Herink MC; Geddes J; Vo K; Zaman A; Hartung DM
J Manag Care Spec Pharm; 2021 Jul; 27(7):856-864. PubMed ID: 34185560
[No Abstract] [Full Text] [Related]
22. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.
Pham TT; Keast SL; Farmer KC; Thompson DM; Rathbun RC; Nesser NJ; Holderread BP; Skrepnek GH
J Manag Care Spec Pharm; 2018 Jul; 24(7):664-676. PubMed ID: 29952711
[TBL] [Abstract][Full Text] [Related]
23. Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C.
Kalidindi Y; Jung J; Feldman R; Riley T
JAMA Netw Open; 2020 Jul; 3(7):e2011055. PubMed ID: 32692371
[TBL] [Abstract][Full Text] [Related]
24. Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use.
Auty SG; Shafer PR; Dusetzina SB; Griffith KN
JAMA Health Forum; 2021 Aug; 2(8):e212285. PubMed ID: 35977199
[TBL] [Abstract][Full Text] [Related]
25. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
[TBL] [Abstract][Full Text] [Related]
26. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
[TBL] [Abstract][Full Text] [Related]
27. Uptake of hepatitis C virus treatment in a multi-state Medicaid population, 2013-2017.
Clements KM; Kunte PS; Clark MA; Gurewich D; Greenwood BC; Sefton L; Pratt C; Person SD; Wessolossky MA
Health Serv Res; 2022 Dec; 57(6):1312-1320. PubMed ID: 35466398
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C Direct-Acting Antiviral Treatment Selection, Treatment Failure, and Use of Drug-Drug Interactions in a State Medicaid Program.
Keast SL; Holderread B; Cothran T; Skrepnek GH
J Manag Care Spec Pharm; 2019 Nov; 25(11):1261-1267. PubMed ID: 31663456
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study.
Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ
J Viral Hepat; 2023 Mar; 30(3):250-261. PubMed ID: 36537024
[TBL] [Abstract][Full Text] [Related]
30. Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment.
Wong RJ; Jain MK; Therapondos G; Shiffman ML; Kshirsagar O; Clark C; Thamer M
Am J Gastroenterol; 2018 Sep; 113(9):1329-1338. PubMed ID: 29523864
[TBL] [Abstract][Full Text] [Related]
31. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.
Corcorran MA; Tsui JI; Scott JD; Dombrowski JC; Glick SN
Drug Alcohol Depend; 2021 Mar; 220():108525. PubMed ID: 33461152
[TBL] [Abstract][Full Text] [Related]
32. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
Iversen J; Wand H; McManus H; Dore GJ; Maher L
Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
[TBL] [Abstract][Full Text] [Related]
33. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
[TBL] [Abstract][Full Text] [Related]
34. Association of the Extension for Community Healthcare Outcomes Project With Use of Direct-Acting Antiviral Treatment Among US Adults With Hepatitis C.
Tran L; Feldman R; Riley T; Jung J
JAMA Netw Open; 2021 Jul; 4(7):e2115523. PubMed ID: 34213557
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study.
Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H
Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914
[TBL] [Abstract][Full Text] [Related]
36. Temporal Trends in Hepatitis C-Related Hospitalizations, United States, 2000-2019.
Hofmeister MG; Zhong Y; Moorman AC; Samuel CR; Teshale EH; Spradling PR
Clin Infect Dis; 2023 Dec; 77(12):1668-1675. PubMed ID: 37463305
[TBL] [Abstract][Full Text] [Related]
37. Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study).
Rolland B; Lions C; Di Beo V; Carrieri P; Authier N; Barré T; Delorme J; Mathurin P; Bailly F; Protopopescu C; Marcellin F
Harm Reduct J; 2022 Oct; 19(1):119. PubMed ID: 36303159
[TBL] [Abstract][Full Text] [Related]
38. Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus.
Kanwal F; Kramer JR; El-Serag HB; Frayne S; Clark J; Cao Y; Taylor T; Smith D; White D; Asch SM
Clin Infect Dis; 2016 Aug; 63(3):291-9. PubMed ID: 27131869
[TBL] [Abstract][Full Text] [Related]
39. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia.
Valerio H; Alavi M; Law M; Tillakeratne S; Amin J; Janjua NZ; Krajden M; George J; Matthews GV; Hajarizadeh B; Degenhardt L; Grebely J; Dore GJ
J Hepatol; 2021 Feb; 74(2):293-302. PubMed ID: 32931879
[TBL] [Abstract][Full Text] [Related]
40. Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors.
Bova S; Cameron A; Durand C; Katzianer J; LeGrand M; Boyer L; Glorioso J; Toman LP
Am J Health Syst Pharm; 2022 Jan; 79(3):173-178. PubMed ID: 33987658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
